Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies

NCT07424833 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT07424833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07424833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 31, 2026
Completion date
December 31, 2031
Enrollment
180 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (cll/sll, relapsed/refractory diffuse large b-cell lymphoma (dlbcl; including richter transformation), relapsed/refractory follicular lymphoma (fl), relapsed/refractory hematological malignancies, relapsed/refractory mantle cell lymphoma (mcl), relapsed/refractory marginal zone lymphoma (mzl), relapsed/refractory waldenström macroglobulinemia (wm)